Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241892 | 0.87 | SMN1; SMN2 (0.40) | KDM4EALDH1A1SMN1; SMN2GRM5CDK8 | |
| SCHEMBL29417058 | 0.83 | ALDH1A1 (0.68) | KDM4EALDH1A1SMN1; SMN2GRM5TLR4 | |
| SCHEMBL13052590 | 0.83 | ALDH1A1 (0.68) | KDM4EALDH1A1SMN1; SMN2GRM5TLR4 | |
| SCHEMBL3237662 | 0.79 | SYK (0.54) | SMN1; SMN2HSD17B1HSD17B2SYKAURKB | |
| SCHEMBL3245556 | 0.78 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2GRM5HTR2C | |
| SCHEMBL23406003 | 0.77 | GRM5 (0.48) | KDM4EALDH1A1SMN1; SMN2GRM5HTR2C | |
| SCHEMBL29744012 | 0.77 | GRM5 (0.48) | KDM4EALDH1A1SMN1; SMN2GRM5HTR2C | |
| SCHEMBL16180061 | 0.76 | HSD17B1 (0.60) | CDK8HSD17B1HSD17B2TRIM24TRIM33 | |
| SCHEMBL510249 | 0.76 | ALDH1A1 (0.70) | KDM4EALDH1A1SMN1; SMN2TLR4TLR2 | |
| SCHEMBL3244438 | 0.75 | CYP1A2 (0.52) | ALDH1A1CDK8AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010057833-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-05-27 | — | — | WO | claimed |
| WO-2010057833-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010057833-A1 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-05-27 | — | — | WO | disclosed |
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050209217-A1 | 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors | BOYLE FRANCIS T | 2005-09-22 | — | — | US | disclosed |
| US-6946468-B1 | 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors | ZENECA LIMITED (GB) | 2005-09-20 | — | — | US | disclosed |
| US-6762170-B1 | ANTIINFLAMMATORY AGENTS INHIBIT LEUKOCYTE RECRUITMENT AND ACTIVATION AND ARE AGONISTS OF THE ADENOSINE 2A RECEPTOR; PENDANT ISOXAZOLE; REACTING A 2,6-DIAMINOPURINE WITH A 2-(3-SUBSTITUTED ISOXAZOL-5-YL)TETRAHYDROFURAN-3,4-DIOL | SMITHKLINEBEECHAM CORPORATION | 2004-07-13 | — | — | US | disclosed |
| EP-1086122-A1 | PYRAZINONE PROTEASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064446-A1 | PYRAZINONE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209217-A1 | 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors | FNTB, FNTA, KRAS | KDM4E 3835/4885ALDH1A1 1024/4885SMN1; SMN2 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.